Clinical Trials Logo

Neuroendocrine Carcinoma clinical trials

View clinical trials related to Neuroendocrine Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03901378 Withdrawn - Clinical trials for Neuroendocrine Carcinoma

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Start date: October 2, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the efficacy, safety, and tolerability of the combination of chemotherapy treatment, which could be either Cisplatin or carboplatin and etoposide, and the research study drug, Pembrolizumab (also known as MK-3475) in patients with high grade neuroendocrine carcinomas of the gastroenteropancreatic system or lung who are chemotherapy naïve. The chemotherapy treatment you receive will be either Cisplatin or carboplatin and etoposide. the participant's doctor will discuss this choice with you and determined which chemotherapy treatment is best for you.

NCT ID: NCT00003514 Withdrawn - Clinical trials for Merkel Cell Carcinoma

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with neuroendocrine tumor that is metastatic or unlikely to respond to surgery or radiation therapy.